U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Application No./Patent No.: 10/581,468 Filed//Issue Date: May 4, 2007 Titled: Treatment Of Inflammatory Bowel Diseases With Anti-lp-10 Antibodies Facet Biotech Corporation
Tritled: Treatment of Inflammatory Bowel Diseases With Anti-Ip-10 Antibodies Facet Biotech Corporation, a
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, povernment agency, etc.) states that it is: 1.
states that it is: 1.
1.
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is
(The extent (by percentage) of its ownership interest is%); or 3 the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either: A An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached. OR B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Balaji Balasa
the patent application/patent identified above, by virtue of either: A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel Frame of the United States Patent and Trademark Office at Reel of
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Real, Frame, or for which a copy therefore is attached. OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Balaji Balasa
the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached. OR B. X A chain of title from the Inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Balaji Balasa
OR B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Balaji Balasa To: PDL BioPharma, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 017974, Frame 0498, or for which a copy thereof is attached.
Reel 017974 1. From: Balaji Balasa To: PDL BioPharma, Inc. The document was recorded in the United States Patent and Trademark Office at Reel 017974 , Frame 0498 , or for which a copy thereof is attached.
The document was recorded in the United States Patent and Trademark Office at Reel $\frac{017974}{}$, Frame $\frac{0498}{}$, or for which a copy thereof is attached.
Reel 017974 , Frame 0498 , or for which a copy thereof is attached.
2. 110m. Hadya Taurushita 10. FDE Dior Hamila, IIIC.
The document was recorded in the United States Patent and Trademark Office at
Reel 017974 , Frame 0498 , or for which a copy thereof is attached.
3. From: Nicholas F. Landolfi To: PDL BioPharma, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 017974 , Frame 0498 , or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee of concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
9 Signature 24 April 2009
Francis Sarena VP, General Counsel & Sec.
Printed or Typed Name Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to 16 (end by the USPTO to process) an application. Confederable by a governed by 35 US, 6.72 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 memors benefity inclinating pathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or expectation. For the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or expectation. See the USPTO. The will vary depending upon the individual case. Any comments on the amount of time your requires to complete this form and/or EVER. Logistic service of the USPTO. The Will vary depending upon the individual case. Any comments on the uniformatic officer. U.S. Patent and Tenderant of Cfriends and Cfriends

Supplemental Sheet

STATEMENT UNDER 37 CFR 3.73(b)

Continuation of Section B .:

From: PDL BioPharma, Inc. To: Facet Biotech Corporation
 The document was recorded in the United States Patent and Trademark Office at Reel 022537, Frame 0440, or for which a copy thereof is attached.